Form 8-K - Current report:
SEC Accession No. 0001628280-24-000193
Filing Date
2024-01-03
Accepted
2024-01-03 16:05:20
Documents
13
Period of Report
2023-12-27
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K frtx-20231227.htm   iXBRL 8-K 32217
5 frtx-20231227_g1.jpg GRAPHIC 29102
  Complete submission text file 0001628280-24-000193.txt   229345

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT frtx-20231227.xsd EX-101.SCH 1905
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT frtx-20231227_lab.xml EX-101.LAB 25156
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT frtx-20231227_pre.xml EX-101.PRE 13052
7 EXTRACTED XBRL INSTANCE DOCUMENT frtx-20231227_htm.xml XML 2826
Mailing Address 5777 CENTRAL AVENUE SUITE 102 BOULDER CO 80301
Business Address 5777 CENTRAL AVENUE SUITE 102 BOULDER CO 80301 (720) 505-4755
Fresh Tracks Therapeutics, Inc. (Filer) CIK: 0000819050 (see all company filings)

EIN.: 930948554 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21088 | Film No.: 24506269
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)